This site is intended for health professionals only
Tuesday 23 January 2018

Top stories

23.01.18: Ixekizumab is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with...
23.01.18: The trial met its primary endpoint of percentage of patients on erenumab (AMG 334) achieving at least a 50% reduction of migraine...
23.01.18: Randomised controlled trial to compare two different treatments and aims to reduce reliance on strong painkillers
16.01.18: Adam Byrne, COO at RealVNC, argues that connected hospitals will facilitate the joining up of health and social care to create truly...
12.01.18: Bezlotoxumab is the first EC licensed non-antibiotic option indicated to prevent Clostridium difficile infection recurrence in high-...
12.01.18: If licensed, ocrelizumab will be the first and only treatment option for adults in the European Union with primary progressive...

Extra news

Adam Byrne, COO at RealVNC, argues that connected hospitals will facilitate the joining up of health and social care to create truly intelligent, proactive healthcare...
It is estimated that up to 5000-6000 nurses and 2000-3000 doctors use point of care testing equipment 24 hours a day
Mark Cusworth examines EU Medical Device Regulation and its implications on labelling – and looks ahead to a Christmas future that could become a nightmare unless...

Supplements

HHE supplements are created to provide readers with dedicated resources and materials for specific areas of healthcare. Click on the images below to access the latest supplements.

2017 eBook

Image